Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386192529> ?p ?o ?g. }
- W4386192529 abstract "Context There has been a dramatic increase in the use of prostate magnetic resonance imaging (MRI) in the diagnostic workup. With prostate volume calculated from MRI, prostate-specific antigen density (PSAD) now is a ready-to-use parameter for prostate cancer (PCa) risk stratification before prostate biopsy, especially among patients with negative MRI or equivocal lesions. Objective In this review, we aimed to evaluate the diagnostic performance of PSAD for clinically significant prostate cancer (CSPCa) among patients who received MRI before prostate biopsy. Evidence acquisition Two investigators performed a systematic review according of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) criteria. Studies (published between January 1, 2012, and December 31, 2021) reporting the diagnostic performance (outcomes) of PSAD (intervention) for CSPCa among men who received prebiopsy prostate MRI and subsequent prostate biopsy (patients), using biopsy pathology as the gold standard (comparison), were eligible for inclusion. Evidence synthesis A total of 1536 papers were identified in PubMed, Scopus, and Embase. Of these, 248 studies were reviewed in detail and 39 were qualified. The pooled sensitivity (SENS) and specificity (SPEC) for diagnosing CSPCa among patients with positive MRI were, respectively, 0.87 and 0.35 for PSAD of 0.1 ng/ml/ml, 0.74 and 0.61 for PSAD of 0.15 ng/ml/ml, and 0.51 and 0.81 for PSAD of 0.2 ng/ml/ml. The pooled SENS and SPEC for diagnosing CSPCa among patients with negative MRI were, respectively, 0.85 and 0.36 for PSAD of 0.1 ng/ml/ml, 0.60 and 0.66 for PSAD of 0.15 ng/ml/ml, and 0.33 and 0.84 for PSAD of 0.2 ng/ml/ml. The pooled SENS and SPEC among patients with Prostate Imaging Reporting and Data System (PI-RADS) 3 or Likert 3 lesions were, respectively, 0.87 and 0.39 for PSAD of 0.1 ng/ml/ml, 0.61 and 0.69 for PSAD of 0.15 ng/ml/ml, and 0.42 and 0.82 for PSAD of 0.2 ng/ml/ml. The post-test probability for CSPCa among patients with negative MRI was 6% if PSAD was <0.15 ng/ml/ml and dropped to 4% if PSAD was <0.10 ng/ml/ml. Conclusions In this systematic review, we quantitatively evaluated the diagnosis performance of PSAD for CSPCa in combination with prostate MRI. It demonstrated a complementary performance and predictive value, especially among patients with negative MRI and PI-RADS 3 or Likert 3 lesions. Integration of PSAD into decision-making for prostate biopsy may facilitate improved risk-adjusted care. Patient summary Prostate-specific antigen density is a ready-to-use parameter in the era of increased magnetic resonance imaging (MRI) use in clinically significant prostate cancer (CSPCa) diagnosis. Findings suggest that the chance of having CSPCa was very low (4% or 6% for those with negative prebiopsy MRI or Prostate Imaging Reporting and Data System (Likert) score 3 lesion, respectively, if the PSAD was <0.10 ng/ml/ml), which may lower the need for biopsy in these patients." @default.
- W4386192529 created "2023-08-27" @default.
- W4386192529 creator A5006391173 @default.
- W4386192529 creator A5049368003 @default.
- W4386192529 creator A5049959252 @default.
- W4386192529 creator A5053198069 @default.
- W4386192529 creator A5064220688 @default.
- W4386192529 creator A5067033760 @default.
- W4386192529 creator A5075165181 @default.
- W4386192529 creator A5083295489 @default.
- W4386192529 creator A5089004130 @default.
- W4386192529 date "2023-08-01" @default.
- W4386192529 modified "2023-09-26" @default.
- W4386192529 title "Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis" @default.
- W4386192529 cites W2060032424 @default.
- W4386192529 cites W2070958949 @default.
- W4386192529 cites W2107638293 @default.
- W4386192529 cites W2111515833 @default.
- W4386192529 cites W2138152245 @default.
- W4386192529 cites W2146373036 @default.
- W4386192529 cites W2288851487 @default.
- W4386192529 cites W2295402589 @default.
- W4386192529 cites W2512180612 @default.
- W4386192529 cites W2549680677 @default.
- W4386192529 cites W2584759710 @default.
- W4386192529 cites W2592656396 @default.
- W4386192529 cites W2764317271 @default.
- W4386192529 cites W2784183204 @default.
- W4386192529 cites W2793905111 @default.
- W4386192529 cites W2801986443 @default.
- W4386192529 cites W2888896143 @default.
- W4386192529 cites W2889108426 @default.
- W4386192529 cites W2893199713 @default.
- W4386192529 cites W2952030907 @default.
- W4386192529 cites W2955216991 @default.
- W4386192529 cites W2970478146 @default.
- W4386192529 cites W2971471165 @default.
- W4386192529 cites W2987369250 @default.
- W4386192529 cites W2993770666 @default.
- W4386192529 cites W2994894232 @default.
- W4386192529 cites W2995275609 @default.
- W4386192529 cites W3012240527 @default.
- W4386192529 cites W3015431020 @default.
- W4386192529 cites W3027017122 @default.
- W4386192529 cites W3035419131 @default.
- W4386192529 cites W3036607405 @default.
- W4386192529 cites W3038472879 @default.
- W4386192529 cites W3044944057 @default.
- W4386192529 cites W3045098776 @default.
- W4386192529 cites W3045681250 @default.
- W4386192529 cites W3083916433 @default.
- W4386192529 cites W3088720245 @default.
- W4386192529 cites W3092486129 @default.
- W4386192529 cites W3093479051 @default.
- W4386192529 cites W3093741058 @default.
- W4386192529 cites W3114746924 @default.
- W4386192529 cites W3140589318 @default.
- W4386192529 cites W3143539160 @default.
- W4386192529 cites W3146142859 @default.
- W4386192529 cites W3152620039 @default.
- W4386192529 cites W3165099959 @default.
- W4386192529 cites W3173242169 @default.
- W4386192529 cites W3175353934 @default.
- W4386192529 cites W3175580364 @default.
- W4386192529 cites W3179856097 @default.
- W4386192529 cites W3186556741 @default.
- W4386192529 cites W3194524670 @default.
- W4386192529 cites W3199460165 @default.
- W4386192529 cites W3213249489 @default.
- W4386192529 cites W3216794373 @default.
- W4386192529 cites W4200278074 @default.
- W4386192529 cites W4226385646 @default.
- W4386192529 cites W4250966750 @default.
- W4386192529 cites W4306774820 @default.
- W4386192529 cites W4376849498 @default.
- W4386192529 cites W3137206333 @default.
- W4386192529 doi "https://doi.org/10.1016/j.euo.2023.08.002" @default.
- W4386192529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37640584" @default.
- W4386192529 hasPublicationYear "2023" @default.
- W4386192529 type Work @default.
- W4386192529 citedByCount "0" @default.
- W4386192529 crossrefType "journal-article" @default.
- W4386192529 hasAuthorship W4386192529A5006391173 @default.
- W4386192529 hasAuthorship W4386192529A5049368003 @default.
- W4386192529 hasAuthorship W4386192529A5049959252 @default.
- W4386192529 hasAuthorship W4386192529A5053198069 @default.
- W4386192529 hasAuthorship W4386192529A5064220688 @default.
- W4386192529 hasAuthorship W4386192529A5067033760 @default.
- W4386192529 hasAuthorship W4386192529A5075165181 @default.
- W4386192529 hasAuthorship W4386192529A5083295489 @default.
- W4386192529 hasAuthorship W4386192529A5089004130 @default.
- W4386192529 hasConcept C121608353 @default.
- W4386192529 hasConcept C126322002 @default.
- W4386192529 hasConcept C126838900 @default.
- W4386192529 hasConcept C126894567 @default.
- W4386192529 hasConcept C143409427 @default.
- W4386192529 hasConcept C151730666 @default.
- W4386192529 hasConcept C2775934546 @default.
- W4386192529 hasConcept C2776235491 @default.
- W4386192529 hasConcept C2779343474 @default.